| Name | Title | Contact Details |
|---|
Hilltop Village-a Retirement is a Euclid, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As one of the largest and fastest-growing Emergency and Hospital Medicine groups in the nation, we partner with more than 5,000 world-class providers who treat more than 6 million patients annually. Physician-led, our team consists of motivated, personable, highly qualified people interested in putting the patient first. We’re committed to doing the right thing for the patients, physicians, and hospitals we serve. Which is why 98% of our physicians recommend us to colleagues and friends. William C. Schumacher, M.D., a board certified emergency medicine physician, formally founded the Schumacher Group in 1994. The philosophy behind Schumacher Group`s founding was based on his belief that there was a better way to deliver and manage emergency medical services in the hospital environment. That `better way` is embodied in our founding mission. The Schumacher Group became known as Schumacher Clinical Partners in 2016.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
QIG Group is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedPro Services is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.